Merck gets FDA nod for skin cancer drug
Merck & Co Inc said the U.S. health regulator approved its drug to treat skin cancer in patients with node-positive melanoma, following removal of the affected part.
Merck's drug Sylatron, which is delivered by a subcutaneous injection, is indicated as an additional treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection.
The company said patients with a history of severe allergic reaction to hepatitis C drugs peginterferon alfa-2b or interferon alfa-2b should not use Sylatron.
Merck said the approval of the drug is based on data from the European Organisation for the Research and Treatment of Cancer.
April 15, 2011